|All Peptides

Read the full guides

DosingBenefitsResultsBuying GuideReconstitutionSide EffectsBloodwork

Semaglutide

Last reviewed: April 18, 2026 by The Peptide Catalog Team

An FDA-approved weight loss injection — clinically proven for 15–20% body weight reduction. Semaglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes and weight management. It reduces appetite, slows gastric emptying, and improves insulin sensitivity, producing 15-20% weight loss in clinical trials. Administered as a once-weekly injection due to its ~7 day half-life.

CategoryWeight Loss & Metabolic Peptides
ClassGLP-1 agonist
GoalFat Loss
Overview

Core Benefits

Key Advantages
~15% weight loss
Drops 15–20% of body weight over a 68-week cycle in trials.
Steady appetite reduction
Cuts hunger and cravings through brain GLP-1 receptors.
Glycemic control
Lowers HbA1c 1.5–2 points in type 2 diabetes trials.
Cardiovascular protection
Cuts major cardiac events 20% in SELECT trial.
Weekly dosing
Once-weekly injection — long half-life keeps levels steady.
Pairs with cagrilintide
CagriSema combo pushes losses to ~22% in Phase 3.

These are educational summaries of commonly discussed effects in wellness/regenerative contexts, not guarantees.

Semaglutide Results Timeline

Progression
1
Week 1–4
Physical Changes
Initial weight loss (2-5 lbs), reduced appetite
Performance & Recovery
Decreased food cravings, smaller portions feel satisfying
Other Benefits
May experience mild nausea (usually resolves), improved energy
2
Month 2–3
Physical Changes
Significant weight loss (5-10%), visible body changes
Performance & Recovery
Sustained appetite control, easier caloric deficit
Other Benefits
Blood sugar improvements, reduced hunger between meals
3
Month 4–6
Physical Changes
Major weight reduction (10-15%), improved body composition
Performance & Recovery
Exercise feels easier at lower weight, more energy
Other Benefits
Cardiovascular markers improve, metabolic health benefits
4
6+ Months
Physical Changes
15-20% total weight loss possible, plateau may occur
Performance & Recovery
Sustained weight maintenance, improved fitness
Other Benefits
Continue until goal weight reached; many use long-term for maintenance

Timeline is illustrative and non-guaranteed. Outcomes vary and are commonly discussed alongside training, nutrition, sleep, and cycling practices.

Read the full Semaglutide results timeline →

Best Kit Deal10-VialCOASave 36%

Ion Peptide — 20mg × 10 (200mg) — $518 $440 with code thepeptidecatalog (15% off) ($2.20/mg)

Evidence at a glance

Two parallel grades per outcome — clinical RCT depth and real-world community adoption. See the Research Overview below for citations and detail.

OutcomeClinical EvidenceCommunity Evidence
Body weight reduction (obesity)StrongStrong
HbA1c reduction in T2DStrongStrong
Cardiovascular event reductionStrongStrong
MASH / liver fibrosisModerateModerate
How It WorksGLP-1 Receptor Agonist — Incretin Mimetic

Receptor → Metabolic Cascade → Weight & Glucose → Outcomes

1
Target

GLP-1 Receptors (Pancreas, Brain, Gut)

Semaglutide mimics the incretin hormone GLP-1, binding receptors in the pancreas (insulin release), brain (appetite suppression), and gut (gastric emptying). Unlike natural GLP-1 which lasts minutes, semaglutide's modifications extend its half-life to ~7 days.

2
Cellular Signal

cAMP/PKA → Insulin Secretion + Central Satiety

GLP-1 receptor activation triggers insulin release from pancreatic beta cells (only when blood sugar is elevated — reducing hypoglycemia risk). In the brain, it activates satiety centers that reduce hunger and food-seeking behavior. In the gut, it slows gastric emptying.

3
Systemic Effect

Reduced Appetite + Improved Glucose → Weight Loss

The combined effects — reduced hunger, slower digestion, improved insulin sensitivity — produce 15-20% body weight reduction in clinical trials. Cardiovascular benefits have also been demonstrated, with reduced risk of major cardiac events.

4
What You Notice

Appetite Reduction → Steady Weight Loss → Metabolic Health

Reduced hunger and food noise are typically noticed within the first week. Weight loss begins within 2-4 weeks and continues steadily. GI side effects (nausea) are common initially but improve with slow titration. Blood sugar improvements measurable within weeks.

What Makes This Peptide Different

Semaglutide is the most widely prescribed GLP-1 for weight lossIts 7-day half-life allows weekly dosing. Compared to Tirzepatide (dual agonist, more weight loss) and Liraglutide (daily dosing, less weight loss), semaglutide offers the best balance of efficacy, convenience, and established safety data.

Research overview

Outcome-by-outcome look at what the evidence actually supports for Semaglutide, including human vs. animal study counts and our editorial take on each.

Body weight reduction in obesity

Clinical:StrongCommunity:Strong

STEP-1 (Wilding 2021, n=1961) randomized adults with overweight/obesity to once-weekly semaglutide 2.4 mg or placebo for 68 weeks and showed mean body weight reduction of 14.9% vs 2.4% placebo. The STEP program (1-8) replicated the effect across diabetic, adolescent, and post-bariatric populations. This is the largest weight-loss effect of any approved chronic weight-management agent prior to tirzepatide.

8 human studies · 6 animal studies

Key findings & citations
  • STEP-1: 14.9% mean weight loss vs 2.4% placebo at 68 weeks.
  • 50.5% of treated patients achieved ≥15% body weight reduction.
  • Effect maintained across multi-year follow-ups; weight regain on discontinuation is documented.

Our take

Until tirzepatide showed up, this was the standard. Still the most widely-prescribed chronic weight-management agent globally.

Cardiovascular outcomes

Clinical:StrongCommunity:Strong

Lincoff 2023 (SELECT, n=17604) showed semaglutide reduced major adverse cardiovascular events by 20% (HR 0.80) in adults with established cardiovascular disease and overweight/obesity *without diabetes*. SUSTAIN-6 (Marso 2016) previously showed CV benefit in T2D. This is the first weight-loss agent with a hard CV outcome benefit in non-diabetic populations.

2 human studies · 4 animal studies

Key findings & citations
  • SELECT: 20% reduction in MACE (HR 0.80, p<0.001) over 40 months in non-diabetic CVD patients.
  • SUSTAIN-6: 26% reduction in MACE in T2D + CVD (HR 0.74).
  • 16.6% discontinuation in semaglutide arm vs 8.2% placebo — GI tolerance is the limiter.

Our take

The first chronic weight-management drug to show cardiovascular benefit independent of glycemic control. Hard outcome data, not surrogate.

MASH / fibrosis

Clinical:ModerateCommunity:Moderate

Newsome 2021 (NEJM, n=320) showed 0.4 mg daily semaglutide produced NASH resolution without fibrosis worsening in 59% of patients vs 17% placebo at 72 weeks. The Phase 3 ESSENCE trial (2025) confirmed the histology benefit but fibrosis improvement remains harder to demonstrate.

1 human study · 4 animal studies

Key findings & citations
  • Newsome 2021: 59% NASH resolution at 0.4 mg vs 17% placebo (p<0.001).
  • Fibrosis stage improvement was not statistically significant in Phase 2.
  • ESSENCE Phase 3 (Sanyal 2025) confirmed MASH histology benefit at 72 weeks.

Our take

Real signal on inflammatory MASH; fibrosis benefit is less clean. Reasonable adjunct in MASH but not a fibrosis-reversal agent.

What Semaglutide doesn't do

Claims that current evidence does not support. Worth knowing before you set expectations.

Top Semaglutide Vendors

#1 VendorNura Peptide25% OFFCOA Verified

$51.75 for 10mg ($5.18/mg) · Score: 10/10

Compare 5 vendors
Calculate your cycle cost →
Dosing ProtocolWeight Loss / Diabetes

Educational reference only. Individual responses vary. Consult healthcare provider before use.

Vial Size
3 mg
Reconstitution
2 ml BAC water
Dose
250 mcg (17 units on 1ml syringe)
Timing
AM
Frequency
Once per week
Duration
8 weeks on, 8 weeks off
Protocol Notes
Take same day each week on empty stomach. Titrate slowly to minimize GI side effects.

Why This Dosing Protocol

Why slow titration? GI side effects (nausea, diarrhea) are dose-dependent. Starting at 0.25mg and increasing every 4 weeks allows the body to adapt, dramatically reducing side effects compared to jumping to full dose.

Why weekly? The albumin-binding acyl chain extends half-life to ~7 days. One injection provides consistent appetite suppression all week — no daily dosing needed.

Why same day each week? Maintains consistent blood levels. Shifting days creates peaks and troughs that can worsen side effects.
Full Dosing GuideReconstitution CalculatorCycle Cost Calculator
Popular Stack Protocols1 stack

Commonly paired protocols from the peptide research community. Educational reference only.

Semaglutide + Tirzepatide

Weight Loss (Sequential)
Semaglutide
Dose
250 mcg weekly
Vial Size
3 mg
Reconstitution
2 ml BAC water
Tirzepatide
Dose
0.5 mg 3x/week
Vial Size
10 mg
Reconstitution
2 ml BAC water
Timing
AM
Frequency
Sequential — not taken simultaneously
Duration
Until goal weight, then maintenance
NOT a simultaneous stack — these are sequential options. Start with semaglutide (GLP-1 only), and if plateauing, transition to tirzepatide (dual GIP/GLP-1) for stronger effects. Some protocols alternate. Never combine both simultaneously due to overlapping GLP-1 receptor agonism and compounding GI side effects.

Reconstitution Calculator

Dilution math and unit conversions. Prefilled using a common vial size for this peptide.

Open calculator

Storage & Handling

Storage at a glance

Proper storage temperatures, shelf life, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.

Powder: Freezer
1+ year at -20°C
Reconstituted: Fridge
4 weeks max at 2-8°C
View Complete Storage Guide

Handling specifics

Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.

Powder storage (very stable)
  • Freezer (-20°C): 1+ year
  • Refrigerator (2-8°C): 1-3 months
  • Room temperature: 2-3 weeks (emergency only)
Reconstituted storage (fragile)
  • MUST refrigerate at 2-8°C
  • 4-week maximum shelf life
  • NEVER freeze after reconstitution
  • Use bacteriostatic water for multi-dose
Molecular Structure

Semaglutide sequence

Click any residue to see its properties.

HydrophobicPolarAcidic (−)Basic (+)Special

Sequence-derived properties

Length
31 residues
Molecular weight
3383.7 Da
backbone only
Avg hydrophobicity
-0.25
Kyte–Doolittle scale

Residue classes

Hydrophobic: 12 (39%)Polar: 7 (23%)Acidic (−): 4 (13%)Basic (+): 4 (13%)Special: 4 (13%)

Net charge distribution

Positive4 (13%)
Neutral23 (74%)
Negative4 (13%)

Amino acid frequency

A×4G×4E×3S×3F×2L×2R×2T×2V×2D×1

Modifications

  • Aib at position 8
  • C18 fatty acid acylation at Lys26
  • Arg substitution at position 34

Sequence and properties provided for educational reference. Not for clinical dosing decisions.

  • Length: 31 amino acids
    (Modified GLP-1 analog.)
  • Half-life: ~7 days
    (Allows weekly dosing.)
  • Mechanism: GLP-1 agonist
    (Incretin mimetic.)
  • Primary Use: Weight loss
    (Appetite suppression + metabolic effects.)
Key modifications
Aib⁸ substitution + C18 fatty diacid at Lys²⁶
The fatty acid side chain binds to albumin, protecting semaglutide from degradation and extending its duration of action compared to native GLP-1 (half-life: 2-3 minutes).
Key takeaway: Semaglutide reduces appetite through central GLP-1 receptor activation, slows gastric emptying, and improves glycemic control. Most effective when combined with lifestyle modifications.

FAQ

How does semaglutide work for weight loss?

Semaglutide mimics GLP-1, a hormone that reduces appetite by acting on brain receptors, slows stomach emptying to increase fullness, and improves insulin sensitivity. This combination leads to reduced calorie intake and significant weight loss — averaging 15-20% of body weight in clinical trials.

Are there different semaglutide formulations?

Yes, semaglutide is available in formulations for type 2 diabetes (lower doses) and weight management (higher doses up to 2.4mg weekly). The active ingredient and mechanism are identical; the difference is approved indication and dosing.

What are the common side effects?

Most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These typically improve over the first few weeks as your body adjusts. Starting at a low dose and gradually increasing helps minimize these effects. Serious but rare side effects include pancreatitis and gallbladder problems.

How long do I need to take semaglutide?

Semaglutide is typically used long-term for weight maintenance. Studies show that weight regain often occurs after discontinuation. Many patients continue indefinitely, though some transition to lower maintenance doses. Discuss your long-term plan with your healthcare provider.

What is the typical semaglutide dosing schedule?

A common research dosage is 250 mcg (17 units on 1ml syringe) injected once per week in the AM on the same day each week. Protocol: 8 weeks on, 8 weeks off. Best taken on an empty stomach. Titrate slowly to minimize GI side effects.

How much weight can I expect to lose on semaglutide?

Clinical trials showed average weight loss of 15-17% of body weight over 68 weeks at the 2.4mg dose. Some patients lose more, some less — results vary based on diet, exercise, and individual response. About one-third of participants lost over 20% of their body weight.

Is semaglutide FDA approved?

Yes, semaglutide is FDA-approved under multiple brand names: for type 2 diabetes and for chronic weight management. An oral version is also approved for diabetes. This makes it one of the most studied and validated weight loss treatments available.

Can semaglutide be used with other weight loss methods?

Yes, semaglutide works best when combined with lifestyle changes including reduced calorie intake and increased physical activity. Clinical trials included lifestyle counseling. Some providers combine it with other approaches, though combining with other GLP-1 drugs is not recommended.

How long does reconstituted peptide last?

Once mixed with bacteriostatic water, peptides remain stable for up to 4 weeks when refrigerated at 2-8°C (36-46°F). Unopened powder can last 1+ year in the freezer. Get our complete Storage & Travel Guide.

Is this peptide legal to purchase?

Peptides sold "for research purposes only" are legal to purchase in the US, but are not FDA-approved for human use outside of specific medical applications. Always consult a healthcare provider before use.

New to peptides?

Take our Peptide Match tool to find the best peptide for your goals. You can also read our Complete Guide to Peptides to learn the basics.

Scientific Sources

The following peer-reviewed studies and official resources provide additional scientific context for this peptide:

Semaglutide Research Articles

guides

Semaglutide Dosage Chart: 250mcg/Week Protocol

Research peptide doses differ dramatically from FDA protocols. Covers 125-500mcg weekly, slow titration, and GI side effect management.

articles

Best Peptides for Liver Health

In trials, semaglutide resolved MASH in 63% of patients — but where do BPC-157 and glutathione really stand? Every liver peptide, evidence-graded.

comparisons

Retatrutide vs Semaglutide: Triple vs Single Agonist

Phase 2 trials reported 24.2% weight loss for retatrutide vs 14.9% for semaglutide in STEP 1 — but only one is FDA-approved. Full side-by-side.

comparison

Cagri+Tirz vs Cagri+Sema: Amylin Pairing Choice

REDEFINE 1 hit 22.7% with cagrilintide + semaglutide. Cagrilintide + tirzepatide has stronger GIP. Mechanistic case, trial data, and the open question.

Compare Semaglutide to alternatives

Side-by-side mechanism, dose, half-life, and vendor pricing.

Open compare →

Disclosure: we may earn affiliate commission from qualifying purchases. Educational information only — not medical advice.